S&P Futures
4,171.00 -20.50 (-0.49%) Dow Futures
34,099.00 +2.00 (+0.01%) Nasdaq Futures
12,658.25 -188.50 (-1.47%) Russell 2000 Futures
2,007.80 -0.10 (-0.00%) Crude Oil
76.05 +0.17 (+0.22%) Gold
1,932.00 +1.20 (+0.06%)
T2 Biosystems, Inc. (TTOO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.5100 |
| Open | 1.5100 |
| Bid | 1.4200 x 900 |
| Ask | 1.4800 x 800 |
| Day's Range | 1.3400 - 1.5938 |
| 52 Week Range | 1.0500 - 29.2500 |
| Volume | |
| Avg. Volume | 164,985 |
| Market Cap | 235.675M |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3860 |
| Earnings Date | Feb 15, 2023 - Feb 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.48 |
- GlobeNewswire
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full Year 2022 and Recent Highlights (unaudited) Achieved full year 2022 total revenue of $22.3 million, including prod
- GlobeNewswire
T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.
LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2C
- GlobeNewswire
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy
LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America. "We are grateful to these distinguished authors for reinforcing the CDC’s call for adoption and implementation of early and accurate microbial diagnosis to guide target
